Jyong Biotech Ltd. MENS
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -63.29%
- 1 year
- -95.58%
- Market cap
- 110.24M
- EPS (ttm)
- -0.06
- Shares out
- 76.03M
- YTD return
- -63.29%
- 1-year return
- -95.58%
- 50-day average
- 40.49
- Volume
- 90.89K
- Avg volume
- 43.09K
- Open
- 1.62
- Previous close
- 1.75
- Day's range
- 1.44 – 1.77
- 52-week range
- 1.45 – 35.40
Key statistics
- 200-day average
- 36.26
- Enterprise value
- 1.16B
- Free cash flow
- -1.73M
- Total cash
- 98.00K
- Total debt
- 18.14M
- Short % of float
- 0.45%
Fundamental scorecard
1 of 25 checks passed on MENS’s reported financials
1of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Dec 31, 2025.
Financials — quick view
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Taiwan
- Website
- jyongbio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MENS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.07% | 53,844 | 157.22K | Sep 29, 2025 |
| HRT Financial LP | 0.03% | 20,819 | 60.79K | Sep 29, 2025 |
| Millennium Management Llc | 0.02% | 13,013 | 38.00K | Sep 29, 2025 |
| Citadel Advisors Llc | 0.02% | 12,641 | 36.91K | Sep 29, 2025 |
| BNP Paribas Financial Markets | 0.00% | 1,698 | 4.96K | Sep 29, 2025 |
| UBS Group AG | 0.00% | 537 | 1.57K | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.05% | 35,802 | 104.54K | Sep 29, 2025 |
| Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 0.02% | 18,042 | 52.68K | Sep 29, 2025 |
